

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Currently Amended) A method of treating or preventing Use of vinpocetine and its or derivatives for the fabrication of a medicine useful in the treatment and prophylaxis of neurological diseases, particularly epilepsy and capable of antagonize the alterations in the auditory brainstem response (ABR) waves and the hearing loss that accompany the illness associated with epilepsy in a patient comprising administering to the patient vinpocetine or a derivative thereof in an amount effective to antagonize alterations in the auditory brainstem response (ABR) waves.

2. (Currently Amended) Use of vinpocetine and its derivatives in accordance with The method of claim 1, the treatment of comprising treating alterations of retro-cochlear origin, characterized by the inhibition of the alterations of the amplitudes and latencies of the later waves of the ABR, namely P3 and P4. in accordance with claim 1, as antiepileptic medication characterized by the inhibition of the epileptic cortical activity for the ictal and post-ictal periods.

3. (Currently Amended) Use in accordance with The method of claim 1, of vinpocetine and its derivatives for the treatment of alterations comprising treating hearing loss of retro-cochlear origin, characterized by the an increase in the auditory threshold induced by pentylenetetrazole or 4-aminopyridine the inhibition of the alterations of the amplitudes and latencies of the different waves of the ABR.

4. (Currently Amended) Use in accordance with The method of claim 1, of comprising administering vinpocetine and its derivatives or a derivative thereof in an amount effective to inhibit the epileptic cortical activity for the ictal and post-ictal periods for the treatment of hearing loss, characterized by the inhibition of the increase in the auditory threshold induced by diverse chemical agents, namely pentylenetetrazole, 4-aminopyridine and several aminoglycoside antibiotics.

5. (Currently Amended) Use in accordance with claim 1 of vinpocetine and its derivatives in the prophylaxis of neurological diseases characterized by the long term protective

~~action on the ABR wave alterations induced by several aminoglycoside antibiotics. The method of claim 1, wherein vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.~~

6. (Currently Amended) The method of claim 2, wherein vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.
~~Use of the medicine of claim 1-5, characterized because it can be administered orally or parenterally in a pharmaceutical acceptable vehicle.~~

7. (New) The method of claim 3, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.

8. (New) The method of claim 4, wherein the vinpocetine or a derivative thereof is administered orally or parenterally in a pharmaceutically acceptable vehicle.